Author

V. Escuret

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:metagenomics· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

B. Lina· 2 shared A. Bal· 1 shared A. Gaymard· 1 shared A. Traversier· 1 shared B. Padey· 1 shared C. Legras-Lachuer· 1 shared C. Nicolas de Lamballerie· 1 shared C. Rheaume· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Lina

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino-acid deletion in nsp2 (Asp268Del)

A. Bal, G. Destras, A. Gaymard, M. Bouscambert-Duchamp, M. Valette, V. Escuret, E. Frobert, G. Billaud, S. Trouillet-Assant, V. Cheynet, K. Brengel-Pesce, F. Morfin, B. Lina, L. Josset

The paper characterizes a SARS-CoV-2 cluster in France, identifying an amino-acid deletion in nsp2 (Asp268Del) present in multiple samples and other European viruses.

bioRxiv · Mar 19, 2020Microbiology

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava

This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.

bioRxiv · Aug 27, 2018Microbiology